These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 1995531

  • 1. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM, Lemmon MJ.
    Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
    [Abstract] [Full Text] [Related]

  • 2. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Mar; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 3. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 4. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM, Lemmon MJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
    [Abstract] [Full Text] [Related]

  • 5. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
    Brown JM, Lemmon MJ.
    Cancer Res; 1990 Dec 15; 50(24):7745-9. PubMed ID: 2253217
    [Abstract] [Full Text] [Related]

  • 6. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 15; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
    Stern S, Guichard M.
    Radiother Oncol; 1996 Nov 01; 41(2):143-9. PubMed ID: 9004358
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul 01; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

  • 10. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P, Huang JM, Ren Y, Zha X, Deng BF, Wu JH, Lang JY.
    Chin J Cancer; 2010 Feb 01; 29(2):126-30. PubMed ID: 20109337
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI, Brown JM.
    Br J Cancer; 1992 Dec 01; 66(6):1053-8. PubMed ID: 1457345
    [Abstract] [Full Text] [Related]

  • 12. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 13. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec 01; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 14. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Dec 01; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 15. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
    Kim IH, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):493-7. PubMed ID: 8005805
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic targets in radiotherapy.
    Brown JM.
    Int J Radiat Oncol Biol Phys; 2001 Feb 01; 49(2):319-26. PubMed ID: 11173124
    [Abstract] [Full Text] [Related]

  • 17. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
    Minchinton AI, Lemmon MJ, Tracy M, Pollart DJ, Martinez AP, Tosto LM, Brown JM.
    Int J Radiat Oncol Biol Phys; 1992 Feb 01; 22(4):701-5. PubMed ID: 1544841
    [Abstract] [Full Text] [Related]

  • 18. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
    Lambin P, Guichard M, Chavaudra N, Malaise EP.
    Radiother Oncol; 1992 Jul 01; 24(3):201-4. PubMed ID: 1410575
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
    el-Said A, Menke D, Dorie MJ, Brown JM.
    Radiat Oncol Investig; 1999 Oct 15; 7(3):163-9. PubMed ID: 10406058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.